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Abstract 
The  Ctr1  family  of  integral  membrane  proteins  is  necessary  for 
high affinity copper uptake in eukaryotes. Ctr1 is also involved 
in cellular accumulation of cisplatin, a platinum-based anticancer 
drug. Although the physiological role of Ctr1 has been revealed, 
the mechanism of action of Ctr1 remains to be elucidated. To 
gain a better understanding of Ctr1-mediated copper and cispla-
tin transport, we have monitored molecular dynamics and trans-
port activities of yeast Saccharomyces cerevisiae Ctr1 and its mutant 
alleles. Co-expression of functional Ctr1 monomers fused with ei-
ther cyan or yellow fluorescent protein resulted in fluorescence 
resonance energy transfer (FRET), which is consistent with multi-
mer assembly of Ctr1. Copper near the Km value of Ctr1 enhanced
 
FRET in a manner that correlated with cellular copper transport. 
In vitro cross-linking of Ctr1 confirmed that copper-induced FRET 
reflects conformational changes within pre-existing Ctr1  com-
plexes. FRET assays in membrane-disrupted cells and protein ex-
tracts showed that intact cell structure is necessary for Ctr1 ac-
tivity. Despite Ctr1-dependent cellular accumulation, cisplatin did 
not change Ctr1 FRET nor did it attenuate copper-induced FRET. 
A Ctr1 allele defective in copper transport enhanced cellular cispl-
atin accumulation. N-terminal methionine-rich motifs that are dis-
pensable for copper transport play a critical role for cisplatin up-
take. Taken together, our data reveal functional roles for structural 
remodeling of the Ctr1 multimeric complex  in  copper  transport 
and suggest distinct mechanisms employed by Ctr1 for copper and 
cisplatin transport. 
Abbreviations: cisplatin, cis-diamminedichloroplatinum(II);  BCS, 
bathocuproine disulfonic acid; ECFP, enhanced cyan fluorescent 
protein; EGS, ethyleneglycol bis(succinimidylsuccinate); EYFP,  en-
hanced yellow fluorescent protein; FRET, fluorescence resonance 
energy transfer; PIPES, 1,4-piperazinediethanesulfonic acid; MES, 4-
morpholineethanesulfonic acid; SC, synthetic complete; ICPMS, in-
ductively coupled plasma mass spectrometry. 
Introduction
Copper is a vital micronutrient required for the normal 
growth and development of many organisms from bacteria 
to humans (1). Copper mediates electron transfer reactions 
by virtue of its ability to donate or accept electrons through 
redox reactions (1). Thus, copper can serve as a cofactor for 
enzymes involved in a variety of essential physiological pro-
cesses, including respiration, free radical detoxification, neu-
rotransmission, iron metabolism, and signaling (1, 2). How-
ever, copper can readily catalyze reactions, which result in 
the production of toxic hydroxyl radicals (3, 4). The essential 
yet toxic nature of copper has been underscored by copper-
related disorders in humans and animals. Nutritional copper 
deficiency leads to defects in growth and development (1, 2). 
Menkes and Wilson diseases are characterized by symptoms 
resulting from copper deficiency and excess accumulation, 
respectively (5–7). Several multifactorial degenerative disor-
ders, such as Alzheimer disease and prion diseases, are also 
linked to imbalances in copper metabolism (8–10). 
Delicate mechanisms for uptake, distribution, storage, 
and excretion of copper are involved in homeostatic copper 
metabolism. The baker’s yeast Saccharomyces cerevisiae has 
been a useful model for the characterization of molecular 
mechanisms of copper metabolism in eukaryotes, because 
the structure and function for most of the molecular compo-
nents involved in homeostatic metabolism of copper in yeast 
are conserved in other eukaryotes, including humans (2, 11–
15). Extracellular copper exists in its oxidized form and is re-
duced by cell surface metalloreductases prior to transport 
(16). Reduced copper appears to be the substrate of Ctr1-me-
diated copper uptake with a Km of 1~5 µM copper (17, 18, 31, 
37). Ctr1 family members have been identified from a vari-
ety of eukaryotes such as yeast, plants, fruit fly, lizard, and 
mammals (12). Characterization of yeast, mice, and human 
cell lines where the Ctr1 gene is deleted or overexpressed 
have demonstrated that Ctr1 is a necessary factor in high af-
finity copper uptake and supplies copper for all known cop-
per-dependent physiological processes (17, 18, 31, 33, 38–
40). Once inside, chaperones such as Atx1 and CCS deliver 
copper to the secretory compartment and to the copper-con-
taining superoxide dismutase, respectively (19–22). Several 
proteins, such as Cox17 and Sco1, are involved in copper in-
sertion into cytochrome c oxidase (23–25). Copper seques-
tration is handled by metallothioneins, which chelate excess 
copper to protect organisms from copper toxicity (26, 27). 
Given that Ctr2 is a vacuolar copper exporter (28), the vacu-
ole may also serve as a copper storage and detoxification or-
ganelle. The copper-dependent transcriptional regulation of 
genes encoding components of copper acquisition and de-
toxification, including Ctr1 and metalloreductases, has been 
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characterized in yeast (2, 12, 15, 26). In addition, copper can 
also trigger the internalization and degradation of Ctr1 in 
yeast and human cells (51, 52). These modes of regulation of 
Ctr1 may play important roles in maintaining optimal lev-
els of copper. However, given that contrasting results have 
been reported as well (58, 59), the nature and physiological 
significance of post-translational regulation of Ctr1 has not 
been firmly established. 
Recent studies have implicated a new role for Ctr1 in the 
cellular accumulation of the chemotherapeutic drug cispla-
tin2 (cis-diamminedichloroplatinum(II)) and its analogues. 
Deletion of the yeast and mouse Ctr1 results in increased cis-
platin resistance and a decrease in cisplatin accumulation 
(60). Human ovarian carcinoma cell lines overexpressing 
Ctr1 exhibit an increase in cisplatin import (62). ATP7A and 
ATP7B, two copper efflux transporters, are also involved in 
cisplatin efflux (63–65). Although these observations suggest 
that cisplatin uptake and extrusion employs copper trans-
porters, the mechanism by which Ctr1 transports the chemi-
cally distinct copper and cisplatin, is poorly understood. 
Ctr1 family members are integral membrane proteins 
spanning three trans-membrane domains (12). Ctr1 proteins 
are unique in their amino acid sequences and structural fea-
tures (12, 15), however site-directed mutagenesis and trunca-
tion of Ctr1 have identified several residues that play roles in 
multimer assembly and copper transport (36, 37, 55, 57). For 
example, the methionine-rich motifs, which reside at the ex-
tracellular surface of Ctr1 family members appear to be in-
volved in enhancing the efficiency of copper transport (36). 
Three conserved methionine residues, one at the extracellu-
lar N terminus and two at the predicted second trans-mem-
brane domain, have been proposed as copper binding resi-
dues during copper translocation (36) (Figure 1A). Several 
lines of biochemical, genetic, and biophysical analyses indi-
cate that Ctr1 multimerizes at the plasma membrane (31,33–
36,54). A recent projection structure of human Ctr1 deter-
mined using two-dimensional cryoelectron crystallography 
further showed that human Ctr1 forms a compact trimer 
with a novel channel-like architecture rather than the struc-
tural design of active transporters (53). This feature of Ctr1 
assembly suggests that copper is translocated through the 
pore formed at the center of the Ctr1 trimer complex. Alter-
natively, like other typical transporters Ctr1-mediated cop-
per translocation may be coupled with structural remodeling 
in the Ctr1 multimeric complex. Because Ctr1 family mem-
bers do not carry a domain that is implicated in ATP utiliza-
tion as a source of energy (2, 17, 12, 31), the electrochemical 
gradient of free copper and/or other ions across the plasma 
membrane may be the driving force for Ctr1-mediated cop-
per transport (31). 
To gain better insights into the mechanisms of action of 
Ctr1, we monitored molecular events coupled with Ctr1 
transport activities and measured cellular copper and cispl-
atin uptake in yeast S. cerevisiae. Co-expression of yeast Ctr1 
monomers tagged with either cyan or yellow fluorescent pro-
tein at the cytoplasmic C terminus resulted in fluorescence 
resonance energy transfer (FRET) in yeast cells. Quantifica-
tion of copper-induced FRET changes between Ctr1 mono-
mers in situ and cross-linking and Western blot analysis of 
Ctr1 showed that copper induces conformational changes of 
the Ctr1 multimeric complex. Correlation of FRET changes in 
Ctr1 with cellular copper uptake revealed an implication of 
structural remodeling of Ctr1 in copper translocation, which 
suggests transporter-like activity of Ctr1. Measurement of 
cisplatin-induced Ctr1 FRET and cellular cisplatin accumu-
lation by Ctr1 mutant alleles showed that the mechanism of 
cisplatin uptake differs from the one employed during cop-
per uptake. 
Experimental Procedures 
Strains, Media, and Growth Conditions—A BY4741 haploid 
S. cerevisiae strain (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0), in 
which Ctr1 gene is knocked out (ctr1::kanMX4) and Ctr3 gene 
is not expressed (Open Biosystems) (43), was used for the ex-
periments. Yeast cells were cultured with synthetic complete 
(SC) media (2% dextrose, 0.2% amino acid mixture, and 0.67% 
yeast nitrogen base) lacking specific markers for plasmid se-
lection or YPD (2% dextrose, 2% Bacto-peptone, 1% yeast ex-
tract) media. Solid media were prepared with the supple-
mentation of 1.5% agar. SUCFM medium (51) (0.67% yeast 
nitrogen base minus copper (Bio 101), 0.08% amino acid mix-
ture, 50 mM MES buffer, pH 6.1) was used for culturing cells 
at low copper growth conditions. Yeast cell growth on non-
fermentable carbon source media was tested using YPEG 
media (2% Bacto-peptone, 1% yeast extract, 2% ethanol, 3% 
glycerol, 1.5% agar). Yeast cells were cultured at 30 °C, if no 
growth temperature is specified. 
Plasmid Construction and Manipulation—Ctr1 and Ctr3 cod-
ing sequence was amplified from yeast genomic DNA by 
PCR using gene-specific primer sets that are flanked by Hin-
dIII (5’-end) and XhoI (3’-end) sites. For the epitope tagging 
at the C terminus of Ctr1, an NotI restriction enzyme site was 
inserted in the reverse primer just before the stop codon. The 
HindIII- and XhoI-digested PCR product was cloned into 
the p415-TEF or p416-TEF yeast vector (44) for a constitutive 
TEF gene promoter-mediated expression of Ctr1 and Ctr3. 
ECFP and EYFP coding sequences without start and stop co-
dons were PCR-amplified from pECFP-C1 and pEYFP plas-
mids (BD Biosciences-Clontech), respectively, with gene-spe-
cific primer sets flanked by NotI sites. The ECFP and EYFP 
PCR products were inserted into the NotI site of Ctr1 cloned 
in p416-TEF and p415-TEF vectors, respectively. A Ctr1 mu-
tant allele carrying a site-directed mutation of the conserved 
methionine (Met-127) to alanine (M1) and a mutant allele 
with a deletion of all eight N terminus Met-rich motifs (Δ8) 
(36) (Figure 1A) was inserted into the same vectors. ECFP or 
EYFP was fused at the C-terminal tail of the Ctr1 mutant al-
leles. All constructs were confirmed by sequencing. Common 
molecular biology techniques, including plasmid amplifica-
tion using Escherichia coli, and purification, followed previ-
ously established methods (45). Plasmid transformation into 
yeast was performed using the lithium acetate method (46). 
Cells transformed with the p415-TEF and p416-TEF vectors 
were selected and maintained using SC media lacking leu-
cine and uracil. 
Functional Assays of Ctr1 Fused with ECFP and EYFP—The 
function of wild-type Ctr1 and Ctr1 fused with either ECFP 
or EYFP was determined by complementation studies in the 
BY4741 yeast strain carrying a Ctr1 deletion (ctr1Δ). Briefly, 
BY4741 ctr1Δ cells expressing empty vector, wild-type Ctr1, 
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or Ctr1 fused with ECFP and EYFP were grown to mid-log 
phase (A600 = 1.0) in SC-selective media. Cells (~5 µl) were 
spotted on YPEG media containing non-fermentable carbon 
sources where BY4741 ctr1Δ cells are not able to grow due 
to a defect in copper-dependent cytochrome c oxidase activ-
ities. Growth of BY4741 ctr1Δ cells transformed with vectors 
expressing Ctr1 or ECFP- or EYFP-fused Ctr1 was compared. 
Fluorescence Microscopy—BY4741 ctr1Δ cells expressing 
wild-type or ECFP-tagged and/or EYFP-tagged Ctr1 were 
grown in SC media lacking leucine and uracil to mid-log 
phase. Cells were visualized using a confocal microscope 
(Olympus FV500) to localize Ctr1-ECFP and Ctr1-EYFP and 
determine the FRET between Ctr1 monomers. Cells were ex-
cited at 433 nm and 500 nm to observe ECFP and EYFP, re-
spectively. Emission signals of ECFP and EYFP were de-
tected at 475 nm and 525 nm, respectively. Images were 
processed using Adobe Photoshop 8.0. 
Quantification of FRET—A scanning fluorometer was used 
to quantify FRET from yeast cells (BY4741 ctr1Δ) co-express-
ing functional Ctr1 tagged with either EYFP or ECFP at the 
C terminus. The method for measuring FRET efficiency in 
yeast cells suspended in buffer using a scanning fluorometry 
has been previously described (47). Briefly, yeast cells cul-
tured to mid-log phase in selective media were washed twice 
using PIPES buffer (50 mM, pH 6.0), and re-suspended in the 
same buffer to A600 1.0 (~107 cells/ml). Fluorescent emission 
spectra by the excitation of ECFP or EYFP were obtained us-
ing a scanning fluorometer (PerkinElmer Life Sciences LS50). 
Cells were excited at 433 nm (ECFP excitation), and the emis-
sion was recorded from 460 nm to 580 nm. The following fac-
tors were considered to calculate the FRET efficiency in cells 
expressing both Ctr1-ECFP and Ctr1-EYFP. First, the emis-
sion spectrum from cells expressing untagged Ctr1 was sub-
tracted to eliminate signal coming from auto fluorescence. 
Second, the emission spectrum of cells expressing Ctr1-ECFP 
and Ctr1 upon excitation of ECFP at 433 nm was obtained. 
This spectrum was subtracted to eliminate emission result-
ing from excitation of ECFP. Third, the emission spectrum 
upon excitation of EYFP at 433 nm of cells expressing Ctr1-
EYFP with untagged Ctr1 was subtracted, which eliminates 
EYFP emission resulting from direct excitation at 433 nm. 
The spectrum obtained after completing these three steps is 
the EYFP emission resulting from FRET. FRET efficiency was 
calculated by dividing the EYFP emission peak area result-
ing from FRET by the peak area of the EYFP emission result-
ing from direct excitation of EYFP at 500 nm. Excel and Igor 
Pro (version 5.0) programs were used for data processing 
and statistical analysis. 
Metal-induced FRET—To measure copper-induced changes 
in FRET, copper (CuCl2, 2.5–25 µM) was added to PIPES buf-
fer (50 mM, pH 6.0) containing yeast cells. Cells were gently 
mixed with copper at room temperature for 0–45 s and were 
scanned with a fluorometer for 75 s (total incubation time, 
75–120 s). To determine metal specificities and cisplatin effect 
on Ctr1 FRET, we applied several metal ions, including silver 
(AgNO3), cobalt (CoSO4), zinc (ZnCl2), and cadmium (CdCl2) 
purchased from Sigma, and cisplatin (American Pharmaceu-
tical Partners Inc. and Sigma). Temperature dependence in 
copper-induced FRET was measured from cells preincubated 
at 0, 10, 25, and 30 °C for 15 min. 
In Vitro FRET Assays—BY4741 ctr1Δ cells transformed 
with Ctr1-ECFP and/or Ctr1-EYFP expression plasmids 
were cultured in selective media to mid-log phase. Cells 
were washed with ice-cold water and suspended in lysis buf-
fer (phosphate-buffered saline, pH 7.5) with protease inhib-
itor mixture (Complete Mini, Roche Applied Science). Cells 
were vortexed with acid-washed glass beads at full speed six 
times for 2 min and centrifuged at 1000 × g for 3 min. The su-
pernatant was considered as a broken-cell fraction. To solu-
bilize proteins, the samples were incubated with Triton X-100 
(1% final concentration) for 30 min on ice, and centrifuged at 
16,000 × g for 15 min. The supernatant containing total pro-
tein extract was collected. Plasma membrane-disrupted cells, 
and total protein extracts were suspended in PIPES buffer 
(50 mM, pH 6.0) at the concentration of 60 µg/ml. FRET effi-
ciency in the samples was measured with or without copper 
supplementation by scanning fluorometry using the same 
method as described above. 
Western Blot Analysis—Protein extracts were denatured 
in SDS sample buffer at 95 °C for 5 min, resolved by SDS-
PAGE, and transferred to a nitrocellulose membrane. Ctr1-
ECFP was detected by chemiluminescence using anti-GFP 
antibodies (1:2,000) that detects not only GFP but also ECFP 
and EYFP, followed by horseradish peroxidase-conjugated 
anti-rabbit IgG antibodies (1:8,000, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Phosphoglycerate kinase was detected 
as loading control by chemiluminescence using anti-phos-
phoglycerate kinase antibodies (1:4,000, Molecular Probes) 
followed by horseradish peroxidase-conjugated anti-mouse 
IgG antibodies (1:10,000, Amersham Biosciences). 
Temperature-dependent 64Cu Uptake Assays—Cells were cul-
tured to mid-log phase in selective media, washed twice using 
PIPES buffer (50 mM, pH 6.0), and re-suspended in the same 
buffer to A600 1.0 (~107 cells/ml). Cells were preincubated at 
0, 10, 25, and 30 °C for 15 min. Radioactive 64Cu (specific ac-
tivity of 15–30 mCi/µg CuCl2, Mallinckrodt Institute of Radi-
ology at Washington University, St. Louis) was added to 1 ml 
of cells to a final concentration of 15 µM, and cells were incu-
bated for 105 s. Samples were quenched with ice-cold phos-
phate-buffered saline containing 10 mM EDTA, filtered, and 
washed twice. 64Cu was quantified using a γ-counter (Perki-
nElmer Life Sciences 1470 Wizard). Values obtained from 
empty vector control cells were subtracted from the values of 
cells expressing Ctr1 and normalized to the cell number. 
Measurement of Cellular Metal Levels—Yeast cells were cul-
tured until mid-log phase, spun down, and resuspended in 
50 mM PIPES buffer (pH 6.0). Cells were cultured with cop-
per or cisplatin, washed two times in phosphate-buffered 
saline containing 10 mM EDTA and 1 mM diethydithiocar-
bamate. Cell pellets were dissolved in 70% nitric acid and 
subsequently diluted to 10% nitric acid. Total cellular metal 
levels were measured by inductively coupled plasma mass 
spectrometry (ICPMS). 
Cisplatin Toxicity Assay—Yeast cells cultured to mid-log 
phase in selective media were washed twice using YPD me-
dia, and re-suspended in YPD to A600 1.0 (~107 cells/ml). 
Cells were cultured at 30 °C for 2 h with or without supple-
mentation of cisplatin (0.5 mM) in the media. Cells were di-
luted and plated on YPD media. Plates were incubated at 30 
°C, and colonies were counted after 2 days. 
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Results 
Ctr1 Multimer Formation in Situ—Yeast Ctr1 tagged at the 
C terminus with enhanced cyan or yellow fluorescent pro-
tein (Ctr1-ECFP or Ctr1-EYFP) (Figure 1A) was constitutively 
expressed in ctr1Δ cells. The functionality of the tagged al-
leles was determined by complementation of the copper de-
ficiency phenotype of yeast cells resulting from the defect of 
endogenous Ctr1 (Figure 1B). Yeast cells lacking Ctr1 (ctr1Δ 
plus vector) cannot grow on YPEG media containing non-
fermentable carbon sources such as ethanol and glycerol due 
to defects in the function of cytochrome c oxidase, a copper-
requiring enzyme (Figure 1B) (17). Yeast cells co-expressing 
untagged (Ctr1-wt) and ECFP or EYFP-tagged Ctr1 (Ctr1-
ECFP or Ctr1-EYFP) did not exhibit any visible difference in 
growth on YPEG media and copper-deficient YPEG media 
supplemented with 100 µM BCS, a copper chelator (YPEG 
plus BCS) (Figure 1B). The growth defect of ctr1Δ yeast cells 
was reversed on YPEG media supplemented with excess cop-
per (100 µM CuCl2) (YPEG plus Cu) and SC media contain-
ing a fermentable carbon source (glucose) lacking uracil and 
leucine (SC) for selection of the transformed plasmids. These 
results demonstrate that Ctr1 fused with ECFP or EYFP is 
fully functional. 
We next examined Ctr1 multimer assembly in situ us-
ing a FRET approach. FRET relies on the distance-depen-
dent (10–100 Å) non-radiative transfer of energy between do-
nor and acceptor chromophores and is a powerful technique 
for studying molecular interactions (41, 42). Aliquots of yeast 
cells expressing combinations of untagged and chromo-
phore-tagged Ctr1 (Ctr1/Ctr1, Ctr1-ECFP/Ctr1, Ctr1/Ctr1-
EYFP, and Ctr1-ECFP/Ctr1-EYFP) were mounted on a glass 
slide and excited at 433 nm (ECFP excitation) and at 500 nm 
(EYFP excitation) using a confocal microscope. Emission sig-
nals for ECFP and EYFP were detected at 475 nm and 525 nm, 
respectively. ECFP and EYFP emission upon excitation with 
the corresponding wavelength is specific to cells expressing 
either ECFP or EYFP (Figure 1C). Yeast cells expressing both 
Ctr1-ECFP and Ctr1-EYFP emit EYFP signal when ECFP is 
excited (Figure 1C), suggesting Ctr1-ECFP and Ctr1-EYFP 
are close enough for FRET to occur (Figure 1D). This is con-
sistent with the formation of multimeric complexes of Ctr1 in 
situ. This FRET signal is specific between Ctr1 monomers, be-
cause cells co-expressing Ctr1-ECFP with Ctr3 C-terminally 
fused with EYFP (34) did not induce FRET (data not shown). 
To confirm the FRET detected in microscopy and to ef-
ficiently quantify it, we measured the FRET signal using a 
scanning fluorometer. Cells expressing non-tagged Ctr1 (Ctr1 
plus Ctr1), ECFP-tagged Ctr1 (Ctr1-ECFP plus Ctr1), EYFP-
tagged Ctr1 (Ctr1 plus Ctr1-EYFP), and ECFP- and EYFP-
tagged Ctr1 (Ctr1-ECFP plus Ctr1-EYFP) were grown over-
night in selective media to mid log phase and suspended 
in PIPES buffer (50 mM, pH 6.0) to A600 1.0 (~107 cells/ml). 
Cells were excited at 433 nm (ECFP excitation) and emission 
was recorded from 460 to 580 nm (Figure 2A). An emission 
peak for ECFP at 475 nm (single triangle) was observed from 
cells expressing Ctr1-ECFP and Ctr1 (dotted line) and Ctr1-
ECFP and Ctr1-EYFP (dashed dot line). An emission peak for 
EYFP (double triangle) at 525 nm upon excitation of ECFP was 
observed from cells expressing Ctr1-ECFP and Ctr1-EYFP or 
Ctr1 and Ctr1-EYFP (dashed line). FRET was calculated as de-
scribed under “Experimental Procedures” and is represented 
by the solid line (Figure 2A). FRET between Ctr1 is consistent 
to the data published by another group (54) during prepara-
tion of this report. To better quantify how efficiently ECFP 
Figure 1.  Formation of functional oligomeric 
complexes by yeast Ctr1 monomers tagged 
with either ECFP or EYFP.  A, schematic depic-
tion of yeast Ctr1 monomer fused with ECFP or 
EYFP at the cytosolic C terminus. The N-termi-
nal extracellular region contains eight Met-rich mo-
tifs. The conserved Met-127 at the N terminus and 
two Met residues at the second transmembrane re-
gion are indicated (*). Three trans-membrane do-
mains are shown as rectangles. B, co-expressed Ctr1 
monomers, tagged with either ECFP or EYFP (Ctr1-
ECFP or Ctr1-EYFP), are functional. Ctr1 knock-out 
(ctr1Δ) cells were co-transformed with two plasmids 
for the constitutive expression of Ctr1 with or with-
out fusion of ECFP or EYFP. Cells (5 µl of A600 = 0.1) 
cultured in synthetic complete media (SC) selecting 
for the two plasmids, were spotted on SC and non-
fermentable (YPEG) growth media without (C) or 
with copper deficiency (100 µM BCS copper chela-
tor supplementation to the media (YPEG plus BCS)) 
or copper addition (100µM CuCl2 (YPEG plus Cu)). 
Cells were grown at 30 °C for 3 days on YPEG me-
dia and for 1 day on SC media before photography. 
C, Ctr1 monomers fused with either ECFP or EYFP 
oligomerize. Cells were excited at 433 nm and 500 
nm to visualize ECFP and EYFP, respectively. Emis-
sion signals of ECFP and EYFP were detected at 475 
nm and 525 nm, respectively, using a confocal mi-
croscope. D, a model of the multimer assembly and 
FRET between Ctr1 monomers fused with ECFP or 
EYFP.
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emission excites EYFP through FRET, we calculated the 
FRET efficiency by dividing the peak area of the FRET emis-
sion by the peak area of the emission spectrum generated by 
exciting cells expressing Ctr1-ECFP and Ctr1-EYFP at 500 nm 
(EYFP excitation) (Figure 2C). The FRET efficiency between 
Ctr1 monomers is 10.1 ± 0.3% (Figure 3D, black bar). To de-
termine whether this FRET signal was specific to interactions 
between Ctr1 monomers or whether it was due to nonspe-
cific collisions between ECFP and EYFP at the plasma mem-
brane, FRET was measured from cells co-expressing Ctr1-
ECFP and Ctr3-EYFP, another trans-membrane protein, or 
cytosolic EYFP. No visible FRET signal was detected in cells 
co-expressing ECFP-tagged Ctr1 with either EYFP-tagged 
Ctr3 (Figure 2B) or EYFP (data not shown). To further deter-
mine whether non-tagged Ctr1 competes for oligomerization 
with the tagged-Ctr1, we overexpressed non-tagged Ctr1 
along with Ctr1-ECFP and Ctr1-EYFP. Indeed, non-tagged 
Ctr1 significantly reduced FRET efficiency to 6.6 ± 0.5% (Fig-
ure 2D, gray bar). Taken together, these results demonstrate 
that FRET between Ctr1 monomers can be efficiently quanti-
fied in live yeast cells using a scanning fluorometer and that 
this signal is specific to Ctr1 monomer interactions in situ. 
Copper Enhances FRET in Ctr1 Multimeric Complexes—To 
determine if the FRET signal produced in Ctr1 multimeric 
complexes is sensitive to copper, yeast cells co-expressing 
Ctr1-ECFP and Ctr1-EYFP were excited in the absence and 
presence of 5 µM copper. Because FRET efficiency correlates 
with the distance between the donor and the acceptor chro-
mophores, the change in FRET efficiency in these complexes 
is indicative of the motion of Ctr1-ECFP and Ctr1-EYFP re-
sulting in a change of the distance between ECFP and EYFP. 
Indeed, FRET between Ctr1-ECFP and Ctr1-EYFP was en-
hanced after the addition of copper (Figure 3A). To deter-
mine time-dependent FRET response after copper exposure, 
cells were prepared as previously described and excited at 
different time points after the addition of 5 µM copper (75–
120 s, 0–45 s incubation at 25 °C and 75 s scanning). The cop-
per-induced FRET efficiency gradually increased and peaked 
close to 2 min before saturating (Figure 3A). Because the
Figure 2.  Determination of FRET between Ctr1-ECFP and Ctr1-
EYFP  in vivo  using a scanning fluorometer.  A, yeast cells express-
ing Ctr1 with or without fusion of ECFP or EYFP were excited at 433 nm 
(ECFP excitation), and the emission spectrum was recorded from 460 nm to 
580 nm. ECFP (▼) and EYFP (▼▼) emission peaks are indicated. FRET data 
were analyzed as described under “Experimental Procedures.” B, FRET ex-
periments were performed on cells expressing Ctr1-ECFP and Ctr3-EYFP 
(Ctr1-ECFP + Ctr3-EYFP). C, determination of FRET efficiency. Cells express-
ing Ctr1-ECFP and Ctr1-EYFP (Ctr1-ECFP + Ctr1-EYFP) were excited at 500 
nm (EYFP excitation) and the emission signal was recorded from 510 nm to 
630 nm (dotted line). FRET was plotted on the same graph (solid line), and 
FRET efficiency was calculated by dividing the FRET peak area by the EYFP 
peak area. D, non-tagged Ctr1 was overexpressed in cells expressing Ctr1-
ECFP and Ctr1-EYFP (Ctr1-ECFP + Ctr1-EYFP + Ctr1). The FRET efficiencies of 
cells expressing Ctr1-ECFP and Ctr1-EYFP (black bar) and of cells express-
ing Ctr1-ECFP and Ctr1-EYFP along with non-tagged Ctr1 (gray bar) were 
compared (* = p < 0.001, Student’s t test). A, B, and C represent the aver-
age and D represents the average and standard deviation of four indepen-
dent experiments.
Figure 3. Copper-induced changes in FRET efficiency between 
Ctr1-ECFP and Ctr1-EYFP.  A, time course of copper-induced FRET in 
Ctr1. Cells were cultured to exponential growth phase, washed, and re-sus-
pended in PIPES buffer (50 mM, pH 6.0) to A600 1.0. Copper (5 µM CuCl2) 
was supplemented to the cell suspension, and FRET efficiency was calculated 
at different time points after the addition of copper (75–120 s, 0–45 s incu-
bation and 75 s scanning) as described under “Experimental Procedures.” B, 
copper dose response of Ctr1 FRET changes with or without ascorbate, a 
copper reductant. Copper (CuCl2, 0.5–25 µM) was supplemented to the cell 
suspension for 30 s, and cells were scanned for 75 s. To reduce copper, CuCl2 
was preincubated with ascorbate (100 mM) for 1 h at room temperature and 
supplemented to cells suspended in PIPES buffer at the shown concentra-
tions (0.1–25 µM). FRET efficiencies obtained with (closed circle) or without 
(open circle) addition of ascorbate were compared. C, metal specificity of Ctr1 
FRET. AgNO3 (Ag), CoSO4 (Co), CdCl2 (Cd), and ZnCl2 (Zn) were applied to 
the cell suspension in the micromolar range, and cells were scanned with a 
fluorometer after addition of the metals. FRET efficiencies were calculated 
and compared. D, temperature dependence of Ctr1 FRET and 64Cu uptake. 
Cells suspended in PIPES buffer were incubated at different temperatures (0, 
10, 25, and 30 °C) for 15 min, prior to the addition of copper (15 µM at 105 
s). Copper-dependent FRET and 64Cu uptake were measured. FRET efficien-
cies (black bars) and 64Cu levels (gray bars) were compared. Each data point 
represents average and standard deviation of at least four independent ex-
periments. *, p < 0.001, Student’s t test.
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scanning by the fluorometer requires 75 s, for short time 
point experiments (1–75 s), cells were fixed in paraformalde-
hyde (4%) under light-protection to minimize bleaching of 
ECFP and EYFP, and then FRET was measured. Copper-in-
duced FRET within 75 s was not statistically significant (data 
not shown). To measure the copper dose response of FRET, 
cells were scanned 30 s after the addition of various copper 
concentrations (2.5–25 µM). A copper-dependent FRET in-
duction was observed in the range of the Km of Ctr1 for cop-
per, and FRET was saturated at higher copper concentrations 
(Figure 3B, open circle). Because reduced copper rather than 
oxidized copper is believed to be a substrate for Ctr1 and 
the reduction is carried on by cell surface metalloreductases 
(16), we tested whether copper reduction is the limiting step 
of copper-induced FRET. Addition of copper preincubated 
with ascorbate (100 mM), a copper reductant, to the FRET as-
say buffer resulted in a dramatic increase in FRET efficiency 
(Figure 3B, closed circle). We next measured FRET efficiency 
changes by other metal ions, including silver, cadmium, 
zinc, and cobalt, by adding micromolar ranges of these met-
als to the assay buffer. Among these metals only silver (15 
µM), which shares similar chemical properties with reduced 
copper (48), exhibited a significant effect on Ctr1 FRET (Fig-
ure 3C). These results further support the conclusion that 
FRET in Ctr1 is a copper-specific response. Because Ctr1-me-
diated copper transport is sensitive to temperature (31), we 
correlated copper-induced FRET with 64Cu uptake at differ-
ent temperatures (Figure 3D). FRET efficiency and 64Cu up-
take were measured in cells suspended in PIPES (50 mM, pH 
6.0) and incubated with 15 µM 64Cu. The FRET efficiency was 
enhanced in a saturable fashion as the incubation tempera-
ture increased (Figure 3D, black bars). 64Cu uptake under the 
same experimental conditions correlated to FRET (Figure 3D, 
gray bars). Consequently, copper-induced FRET in Ctr1 mir-
rored the characteristics of Ctr1-mediated copper uptake. 
Defect in Copper-induced FRET in a Non-functional Ctr1 
(M127A) Mutant—We next asked whether copper would 
have the same effect on FRET from a non-functional Ctr1 
mutant. A Ctr1 mutant possessing a conserved extracellu-
lar methionine (Met-127) to alanine mutation (M1) (36) was 
fused with ECFP and/or EYFP. Two independent constructs 
were co-transformed in Ctr1 knock-out yeast cells. Expres-
sion and localization of the M1 mutant alleles is indistin-
guishable from that of wild-type Ctr1, but they are non-func-
tional in copper transport (data not shown). FRET between 
the M1 mutants demonstrated that they form multimeric 
complexes (Figure 4, A and B). However, no copper-induced 
FRET was observed in the M1 multimer at copper concen-
trations up to 25 µM (Figure 4B). This further suggests that 
copper-induced FRET in Ctr1 is coupled with copper trans-
port. To test whether the copper transported into the cyto-
plasm by other pathways induces Ctr1 FRET, we expressed 
Ctr3 along with the non-functional mutant M1 tagged with 
either ECFP or EYFP. Ctr3 is a Ctr1 family member in yeast 
that is functionally redundant to Ctr1, and our FRET assay 
between Ctr1 and Ctr3 showed that they do not physically 
interact in vivo (Figure 2B). Ctr3 co-expressed with M1 mu-
tants enhanced intracellular copper accumulation as deter-
mined by growth assay on copper-requiring media (data not 
shown). However, intracellular copper transported through 
Ctr3 did not lead to copper-dependent FRET changes be-
Figure 4.  Effect of copper on the FRET between non-functional 
Ctr1 monomers.  A, FRET was determined from cells transformed with 
two plasmids constitutively expressing non-functional M127A Ctr1 mutants 
(M1) with or without ECFP and/or EYFP fusion at the C terminus. B, copper-
dependent FRET in the M127A mutant Ctr1. Copper (CuCl2, 2.5 ~25 µM) 
was added to the yeast cells suspended in PIPES buffer for 30 s, and the cells 
were scanned for 75 s using a scanning fluorometer. FRET efficiencies as a 
function of copper concentrations were calculated as described under “Ex-
perimental Procedures” and compared. Each data point represents the av-
erage and standard deviation of four independent experiments. C, FRET was 
measured without or with copper (15 µM CuCl2 for 30 s) supplementation 
on cells expressing functional Ctr3 along with the non-functional M1 mu-
tant tagged with either ECFP or EYFP. FRET efficiencies were calculated (gray 
bars) and compared with the efficiencies of cells expressing only ECFP- and 
EYFP-tagged M1 (black bars).
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tween the M1 mutants (Figure 4C), suggesting that copper-
induced FRET in Ctr1 is coupled with the copper movement 
through the Ctr1 channel. Interestingly, Ctr3 co-expression 
reduced FRET in the M1 mutant multimers (Figure 4C), pos-
sibly because Ctr3 may sequester other cellular component(s) 
that influence FRET in Ctr1. 
Copper-induced FRET Changes in Ctr1 Occur as a Conse-
quence of Conformational Changes in Pre-existing Ctr1 Com-
plexes—We next examined copper-dependent Ctr1 structural 
changes using an in vitro protein cross-linking approach. To-
tal protein extracts were prepared from yeast cells express-
ing Ctr1-ECFP cultured in media with or without copper 
(5 µM, 2 min) supplementation. The protein extracts were 
cross-linked using ethyleneglycol bis(succinimidylsuccin
ate) (EGS), which is a primary amine cross-linker and sep-
arated on SDS-PAGE. Ctr1-ECFP was detected by Western 
blot analysis using anti-GFP antibodies (Figure 5). Increas-
ing EGS concentrations shifted all the monomeric species of 
Ctr1 to the predicted homotrimer and higher oligomeric spe-
cies suggesting that Ctr1 exists as a multimer in total protein 
extracts. Because phosphoglycerate kinase in the samples is 
detected as a monomeric species, the cross-linking is Ctr1 
specific. Interestingly, cross-linking of Ctr1 to multimeric 
species was much more efficient in protein extracts prepared 
from copper-treated cells when compared with protein ex-
tracts from control cells (Figure 5, lane 2 versus lane 6). Ctr1 
in cells cultured with copper-supplemented media likely car-
ries a distinct conformation that is more favorable for EGS 
cross-linking. Moreover, these data suggest that the cop-
per-induced FRET (Figure 3) must represent conformational 
changes, which occur in pre-existing multimer complexes 
rather than new multimer formation, because all of the Ctr1 
exists as trimer and higher complexes in both control and 
copper-treated cells (Figure 5, lanes 4 and 8). 
In Vitro FRET Assays Showed That Proper Location of Ctr1 Is 
Necessary for Its Function—Copper uptake is not dependent 
on cellular ATP levels (31), but it appears that extracellular
K+ and acidic pH stimulate copper uptake (31, 50). Trans-
membrane ionic gradients are known to be an important fac-
tor for several transport mechanisms, such as co-transport 
of proton and iron through DMT1 (DCT1 or Nramp2) diva-
lent metal transporter (49). To examine the roles for trans-
membrane ionic gradient in Ctr1 activity, we measured Ctr1 
FRET in membrane-disrupted cells and protein extracts from 
cells expressing ECFP or EYFPfused Ctr1. The plasma mem-
brane was perturbed by vortexing cells with glass beads as 
described under “Experimental Procedures.” No live yeast 
cells remained under these conditions as confirmed by a cell 
growth assay on solid media (data not shown). Total pro-
tein extract was prepared by incubation of broken cells with 
1% Triton X-100. The samples were suspended in PIPES buf-
fer, and FRET was measured using a scanning fluorometer. 
FRET in broken cells and protein extracts was similar to that 
in intact cells (Figure 6), suggesting that Ctr1 maintains a 
multimeric complex in these samples. However, copper did 
not enhance FRET (Figure 6), suggesting no changes in the 
conformation of the Ctr1 multimer complex. To account for 
the possibility that copper reductases are not active under 
these experimental conditions, FRET induced by copper pre-
incubated with ascorbate was measured. However, reduced 
copper again had no effect on Ctr1 FRET (data not shown). 
These data suggest that Ctr1 location at intact cell mem-
branes is necessary for acquiring a driving force for confor-
mational changes. 
Cisplatin Does Not Induce Ctr1 FRET or Compete with Cop-
per for FRET—Genetic and biochemical studies in yeast and 
mammalian cells have convincingly demonstrated that Ctr1 
is a major factor for cellular accumulation of cisplatin (60–63, 
66). However, it is still unclear whether Ctr1-mediated cispla-
tin accumulation employs the same mechanism used for cop-
per uptake, particularly when considering the difference in 
Figure 5. In vitro cross-linking of the Ctr1 oligomeric complex to as-
certain copper-dependent Ctr1 conformational changes. Ctr1 knock-
out cells expressing Ctr1-ECFP and Ctr1-EYFP were cultured in synthetic 
complete media with or without copper supplementation (5µM for 2 min). 
Total protein extracts were incubated with a primary amine cross-linker EGS 
at the shown concentrations and resolved by non-reducing SDS-PAGE. Ctr1 
was detected by Western blot analysis with anti-GFP antibodies. Phospho-
glycerate kinase (PGK) in the same samples was detected using anti-phospho-
glycerate kinase antibodies as a control of specificity of Ctr1 cross-linking. 
Bands corresponding to the monomer and trimer species of Ctr1-ECFP are 
indicated with one and three black ovals, respectively.
Figure 6. In vitro FRET analyses. Yeast cells expressing Ctr1 with or with-
out fusion of ECFP or EYFP were vortexed with glass beads to perturb the 
membrane structure. Total proteins were extracted from the samples using 
Triton X-100 (1% final concentration). The broken cells (Membrane plus Cy-
toplasm, black bars) and protein extracts (gray bars) were re-suspended in 
PIPES buffer (60 µg/ml). Ctr1 FRET efficiency in the samples was measured 
using a scanning fluorometer in the presence or absence of copper (15 µM 
CuCl2 for 30 s). Each data point represents the average and standard devia-
tion of four independent experiments.
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structure and chemical properties between cisplatin and cop-
per. Because copper enhanced Ctr1 FRET in a manner that 
correlated with cellular copper uptake, we inquired whether 
cisplatin would have the same effect. Yeast cells co-express-
ing Ctr1-ECFP and Ctr1-EYFP were excited in the absence 
and presence of cisplatin. However, FRET between Ctr1-
ECFP and Ctr1-EYFP was not changed after the addition of 
various concentrations of cisplatin (Figure 7A) even after 5 
min of exposure (Figure 7B). To determine whether cells 
were accumulating cisplatin, platinum levels in cells were 
measured under the experimental condition used for FRET 
analysis. Cells were suspended in PIPES (50 mM, pH 6.0) and 
incubated either with 100 µM cisplatin for 105 s or 50 µM cis-
platin for 300 s. Cell associated platinum was measured us-
ing ICPMS. Under both conditions cisplatin was at least one 
and a half times higher in cells expressing Ctr1 (Figure 7C, 
gray bars) when compared with control cells expressing an 
empty vector (Figure 7C, black bars), which shows that Ctr1 
enhances cellular cisplatin levels despite no FRET change be-
ing observed. To determine whether cisplatin could attenu-
ate the effect of copper on Ctr1 FRET through competition, 
we measured Ctr1 FRET in cells suspended in PIPES (50 mM, 
pH 6.0) and incubated with 15 µM copper in the presence or 
absence of 50 µM cisplatin (Figure 7D). Copper enhancement 
of Ctr1 FRET efficiency was not significantly changed in the 
presence of excess cisplatin. 
Cisplatin Accumulation and Toxicity in Cells Expressing Ctr1 
Mutants—We next tested whether cisplatin could accumu-
late in cells expressing the Ctr1 (M127A) mutant (M1), which 
is defective in copper uptake (36) and does not display cop-
per-enhanced FRET (Figure 4B). ctr1Δ cells expressing ei-
ther empty vector, Ctr1, or Ctr1(M127A) mutant (M1) were 
grown to mid-log phase resuspended in PIPES (50 mM, pH 
6.0) and incubated with 15 µM copper or 50 µM cisplatin for 
300 s. Cell-associated copper and cisplatin were measured us-
ing ICPMS. As expected the non-functional mutant M1 failed 
to accumulate copper (Figure 8A). However, accumulation of 
platinum in cells expressing either Ctr1(M127A) or wild-type 
Ctr1 was similar to each other (Figure 8B), suggesting that the 
Ctr1 mutant defective in copper uptake is able to enhance cel-
lular cisplatin levels. Because it was proposed that cisplatin in-
duces multimer stabilization of human Ctr1 through N-termi-
nal methionine-rich motifs (67), we tested whether yeast cells 
expressing a Ctr1 allele with a deletion of all eight N terminus 
Met-rich motifs (Δ8) could accumulate cisplatin. In contrast to 
enhanced copper transport by the Δ8 mutant (Figure 8A), no 
difference in cellular cisplatin accumulation was observed in 
cells expressing Δ8 when compared with cells expressing an 
empty vector (Figure 8B). We next correlated cellular cisplatin 
accumulation with sensitivity to cisplatin. Because cells lack-
ing Ctr1 or expressing the non-functional M1 allele are gener-
ally less healthy when compared with cells expressing a func-
tional Ctr1, we co-expressed Ctr3 copper transporter in cells 
expressing vector, wild-type Ctr1, M1, or Δ8. Ctr3 does not af-
fect cisplatin uptake (60). Cells were cultured in YPD media 
for 2 h with or without supplementation of 0.5 mM cisplatin, 
and plated on YPD media (60). After 2 days cell survival was 
measured as a percentage of colonies from cisplatin-treated 
cultures compared with colonies from controls. Consistent to 
the fact that Δ8 does not affect cellular cisplatin accumulation, 
yeast cells expressing Δ8 showed resistance to cisplatin when 
compared with cells expressing Ctr1 or M1 (Figure 8C). These 
data suggest a critical role for the N-terminal Met-rich motifs, 
but not for the conserved Met-127, in Ctr1-mediated accumu-
lation and toxicity of cisplatin. 
Discussion
Physiological roles of Ctr1 in both copper transport and 
cellular cisplatin accumulation have been established. How-
ever the mechanisms of action employed by Ctr1 during 
these processes remain poorly understood. Our data support 
the conclusion that Ctr1-mediated copper transport is cou-
pled with structural rearrangements of Ctr1 mutimeric com-
plexes. This suggests that Ctr1 possesses transporter activity 
rather than serving as a pore for copper translocation across 
the plasma membrane, even though it was shown that Ctr1 
forms a structure similar to an ion channel and the trans-
membrane pore is not structurally occluded (53). Moreover, 
monitoring cisplatin-induced FRET and cellular cisplatin ac-
cumulation by mutant Ctr1 alleles revealed that the mech-
anism for Ctr1-mediated cisplatin transport is distinct from 
that of copper. 
Although yeast Ctr1 possesses a relatively long (~127 
amino acids) C-terminal tail compared with other family 
members (12), ECFP and EYFP independently fused at the 
Figure 7. Effect of cisplatin on the Ctr1 FRET and Ctr1-dependent 
cellular cisplatin accumulation. A, cisplatin dose-response of Ctr1 FRET. 
Yeast cells expressing Ctr1 with or without fusion of ECFP or EYFP were cul-
tured to exponential growth phase, washed, and re-suspended in PIPES buf-
fer (50 mM, pH 6.0) to A600 1.0. Cisplatin (25–100 µM) was supplemented to 
the cell suspension for 30 s and cells were scanned for 75 s. FRET efficiency 
was compared. B, time dependence of cisplatin-induced Ctr1 FRET. Cispla-
tin (50 µM) was supplemented to the cell suspension. Cells were scanned at 
105 and 300 s after the addition of cisplatin (30 and 225 s incubation, respec-
tively, and 75 s scanning). FRET efficiency was compared. C, cells treated with 
cisplatin under the same conditions as FRET were collected and washed, and 
cellular platinum levels were measured using ICPMS. D, effect of cisplatin on 
copper-enhanced Ctr1 FRET. FRET efficiencies were measured in cells re-
suspended in PIPES buffer to A600 1.0 with or without copper (15 µM) and 
cisplatin (100 µM). Data represent the average ± S.D. of four independent 
measurements. Statistical significance between data were compared by Stu-
dent’s t test as indicated.
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end of the C terminus of Ctr1 are within a distance in which 
FRET can occur. This suggests that yeast Ctr1 is composed 
with at least two Ctr1 monomers in situ. Given that human 
Ctr1 forms a homotrimer (53), yeast Ctr1 likely forms a tri-
meric complex as well. However, our in vitro cross-linking 
and Western blot analysis of ECFP-fused Ctr1 interestingly 
showed not only a predicted trimer but also higher molecu-
lar weight complexes. It is possible that yeast Ctr1 may form 
a homo multimer complex higher than a trimer or associate 
with other proteins to form a functional copper transporter. 
Functional hetero and homo multimers have been observed 
in many transporters and ion channels. For example, P2X 
chloride channels and TRP channels are assembled by either 
homo or hetero multimerization of monomeric isoforms (68, 
69). It is interesting to note that Ctr4 and Ctr5 two distinct 
Ctr1 homologues in Schizosaccharomyces pombe form a hetero-
multimeric complex, which is necessary for proper localiza-
tion of each subunit to the plasma membrane and transporter 
activity (35). However, FRET analysis between Ctr1 and Ctr3 
suggests that these Ctr1 family members do not form hetero-
multimers. Given that humans, plants, and fruit flies as well 
as yeast express more than one Ctr1 family proteins (12), the 
possibility of heteromultimer formation between Ctr1 family 
members in these species remains to be tested. 
Quantification of FRET in a suspension of yeast cells us-
ing a scanning fluorometer is an efficient and powerful 
method for determining protein-protein interactions in situ 
and monitoring subtle and transient conformational changes 
associated with protein activities. Extracellular copper spe-
cifically enhanced FRET between ECFP- and EYFP-tagged 
Ctr1 monomers and intracellular copper transported by 
other pathways does not induce Ctr1 FRET. Thus, copper 
binding in the extracellular domain of Ctr1 must be transmit-
ted through the transmembrane domains of Ctr1. Consider-
ing that FRET is proportional to the distance between the do-
nor and acceptor (41, 42), enhanced FRET between ECFP and 
EYFP is a clear indication of motion of the cytosolic C termini 
leading to a shorter distance between the two fluorophores. 
Several lines of evidence presented in this study strongly 
suggest that copper-induced FRET is associated with Ctr1-
mediated copper transport. First, the changes in FRET in re-
sponse to copper correlate with the characteristics of Ctr1-
mediated copper uptake. Second, the copper-induced FRET 
does not occur in a non-functional Ctr1 complex. This obser-
vation suggests that, despite the fact that Ctr1 forms a chan-
nel-like architecture carrying an unoccluded pore at the sym-
metric subunit interface (53), Ctr1 behaves like a transporter 
rather than a pore during copper transport. Although the ho-
mology in amino acid sequences of Ctr1 family members is 
not significant (12), biochemical and genetic analyses of the 
structure-function relations of yeast and human Ctr1 have 
suggested that the mode of action is conserved among Ctr1 
family members (36). The conformational changes observed 
in yeast Ctr1 complexes likely occur in other Ctr1 family 
members, including human Ctr1. Consistently, it has been 
reported that the presence of copper during tryptic cleavage 
of human Ctr1 results in protection of the cytoplasmic loop 
between the predicted first and second transmembrane do-
mains (37), which independently suggests copper-induced 
conformational changes in a Ctr1 family member. 
Figure 8. Ctr1 mutant defective in copper uptake enhances cellu-
lar accumulation of cisplatin. A, BY4741 ctr1Δ cells transformed with ei-
ther empty vector (V), wild-type Ctr1 (WT), M127A Ctr1 (M1), or Ctr1 lack-
ing all N-terminal eight Met-rich motifs (Δ8) were cultured in selective media 
to mid-log phase, resuspended in 50 mM PIPES (pH 6.0) and cultured with 15 
µM copper at 30 °C for 5 min. Cells were collected and washed with PIPES 
buffer containing EDTA (10 mM), and cell-associated copper levels were mea-
sured by ICPMS. Data represent the average ± S.D. of four independent mea-
surements. B, cells prepared as in A, were cultured with 50 µM cisplatin at 30 
°C for 5 min. Cells were collected and washed with PIPES buffer containing 
cisplatin chelator diethydithiocarbamate (1 mM), and cell-associated platinum 
levels were measured by ICPMS. C, cisplatin sensitivity conferred by Ctr1 
wild-type and mutants. BY4741 ctr1Δ cells expressing Ctr3 transformed with 
either empty vector (V), wild-type Ctr1 (WT), M127A Ctr1 (M1), or Ctr1 
lacking all N-terminal eight Met-rich motifs (Δ8) expression construct. Cells 
grown in the plasmid selection media were re-suspended in YPD media (A600 
1.0) and were cultured at 30 °C for 2 h with or without 0.5 mM cisplatin 
supplementation. Cells were diluted and plated on YPD solid media. After in-
cubating the plates at 30 °C for 2 days, growing colonies were counted. Data 
are expressed as percentages of colonies formed from cells exposed to cispl-
atin compared with colonies formed from control cells. Statistical significance 
between data were compared by Student’s t test as indicated.
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Previous studies on Ctr1-mediated copper transport in a 
mammalian cell line showed that proton and potassium lev-
els in buffer or culture media affect Ctr1 activity (31), how-
ever the role of the transmembrane ionic gradient in Ctr1-
mediated copper transport remains to be elucidated. Ctr1 in 
either membrane patches or protein extracts prepared using 
a buffer containing 1% Triton X-100 exhibited FRET, suggest-
ing that Ctr1 still maintains a multimer complex under these 
conditions. However, copper did not induce FRET changes 
in Ctr1. Copper-induced structural changes in Ctr1 appear 
to require a specific environment maintained by live cells. A 
Ctr1 functional assay using purified Ctr1 or heterologous ex-
pression systems and structural characterization of Ctr1 in vi-
tro may not reflect activity and structure of Ctr1 as expressed 
in its natural environment. 
We propose that conformational changes in the Ctr1 mul-
timeric complex play important roles in function and regu-
lation of Ctr1. Copper binding to Ctr1 may initiate confor-
mational changes that are transduced throughout the Ctr1 
channel culminating with a motion of the C terminus tail 
when copper is released into the cytoplasm. Structure-func-
tion analysis of Ctr1 showed that three Met residues con-
served throughout the Ctr1 family of proteins are necessary 
for Ctr1-mediated copper transport (36). These Met resi-
dues located at the extracellular N-terminal domain (~20 
amino acids away from the first transmembrane domain) 
and the second transmembrane domain have been pro-
posed as copper-binding residues (36). The three conserved 
methionines may serve as a selective filter for copper. Con-
sidering that Ctr1 forms a homotrimer, the external face of 
Ctr1 carries at least nine Met residues. However, no appar-
ent copper binding residues, such as Met, Cys, and His, are 
conserved throughout the rest of the transmembrane re-
gion of Ctr1 family members. Thus, it is uncertain how cop-
per moves from the periplasmic side to the cytoplasm and 
whether it is coordinated when it traverses the channel. Con-
formational rearrangement of the Ctr1 transmembrane do-
main induced by copper binding at the cell surface may be 
sufficient for removing the steric barrier(s) formed in the 
transmembrane pore. High-resolution snapshot structures 
of Ctr1 multimeric complexes in the copper-translocation cy-
cle would further elucidate the dynamics of Ctr1 which we 
have observed in living cells. When copper reaches the cy-
toplasmic end of the pore, the cytoplasmic domains may co-
ordinate copper and may be involved in its subsequent re-
lay to cytoplasmic carriers. A few predicted copper binding 
residues, including at least one conserved cysteine residue, 
are present in these domains (data not shown). Because it has 
been shown that virtually no free copper exists in cells (70), 
it is reasonable to predict that interactions between intracel-
lular copper chaperones and Ctr1 may be involved in effi-
cient copper transport without releasing copper to the cyto-
plasm. FRET between Ctr1 and copper chaperones would be 
a useful approach for gaining further insights into molecular 
mechanisms of copper uptake across the plasma membrane. 
In addition, structural remodeling of Ctr1 may be implicated 
in regulation of its activity and expression at the cell surface. 
Copper-induced conformational changes in Ctr1 may expose 
regulatory domains or lead to formation of new domains, 
which attract other components of the copper uptake sys-
tem. Because it was reported that Ctr1 in yeast and mamma-
lian cells undergoes copper-induced endocytosis and degra-
dation (51, 52), a specific conformation of Ctr1 resulting from 
excess copper exposure may recruit the machinery involved 
in the post-translational regulation of Ctr1. 
An interesting dilemma about the structure and function 
of Ctr1 implicates the role of this transporter in the uptake of 
cisplatin, a widely used and effective cancer chemotherapy 
agent. Treatment failure is often associated with increased re-
sistance to this drug. Cisplatin resistance has been ascribed 
to various mechanisms, including decreased accumulation, 
increased efflux, enhanced cellular detoxification, and DNA 
damage repair (71–73). Several previous reports suggest an 
implication of copper metabolism pathways in the uptake, 
chelation, and extrusion of cisplatin. Ctr1 is an important fac-
tor determining cellular cisplatin accumulation (60–62). Cispl-
atin can also induce expression of metallothionein, a chelator 
of copper and other metal ions (56, 76). Enhanced expression 
of copper efflux P-type ATPases has been observed in cispl-
atin-resistant cancer cells (63–65). However, the mechanistic 
basis of the implication of copper metabolic pathways in cis-
platin metabolism remains uncertain. Our data clearly show 
that, despite Ctr1-dependent cellular accumulation, cisplatin 
did not affect Ctr1 FRET. Moreover, a Ctr1 mutant defective 
in copper uptake enhances cisplatin accumulation, whereas 
a copper transport-active Ctr1 mutant lacking all eight N ter-
minus Met-rich motifs did not accumulate cisplatin. Together 
these data suggest that Ctr1 employs a different mechanism 
for copper and cisplatin transport and the rapid conforma-
tional changes in Ctr1 observed during copper translocation 
are not coupled with cisplatin uptake. The N-terminal Met-
rich motifs seem to play a significant role for Ctr1-mediated 
cisplatin uptake. It is possible that binding of cisplatin to the 
N terminus of Ctr1 followed by subsequent internalization 
could be a mechanism for cisplatin uptake. The competition 
between copper and cisplatin in their uptake (60) may be due 
to internalization of Ctr1 by either copper and/or cisplatin, 
which would reduce the availability of Ctr1 at the cell surface 
thus reducing the uptake of either copper or cisplatin. How-
ever, copper- and cisplatin-induced internalization of Ctr1 
(60, 74, 75) has been challenged by contrasting results indicat-
ing no effect of cisplatin on steady-state location of Ctr1 (58, 
59, 67). Further elucidation of the mechanism of action and 
regulation of Ctr1 would lead to a better understanding of 
how Ctr1 can transport the essential mineral copper and the 
anticancer drug cisplatin and whether abnormal Ctr1 func-
tion and regulation is linked to the development of cisplatin 
resistance in cancer patients. 
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